Retatrutide's Glucagon Paradox: Why Adding It Helps

If you know anything about type 2 diabetes pharmacology, your first reaction to retatrutide's design is probably confusion. Semaglutide and tirzepatide suppress glucagon — that's a feature, because glucagon raises blood sugar. Retatrutide adds a glucagon receptor agonist to the mix. On the surface, that looks like putting one foot on the gas and one foot on the brake.

It isn't. The retatrutide glucagon component is counterintuitive but pharmacologically coherent, and understanding it explains why retatrutide's Phase 2 weight loss numbers — 24.2% at 48 weeks on the 12 mg dose — appear to exceed what GLP-1/GIP dual agonism can achieve.

What glucagon normally does

Glucagon is the counter-regulatory partner to insulin. When blood glucose drops, the alpha cells of the pancreas secrete glucagon to raise it back up. Glucagon acts on the liver to:

• Break down glycogen stores into glucose (glycogenolysis)
• Build new glucose from amino acids and other precursors (gluconeogenesis)
• Promote fatty acid release from fat cells (lipolysis)
• Increase ketone production

In classical T2D pathology, glucagon is dysregulated — it keeps firing even when blood sugar is already high, which drives further hyperglycemia. GLP-1 receptor agonists partly work by suppressing inappropriate glucagon secretion from alpha cells. So adding glucagon agonism to a GLP-1 drug seems to work against the drug's own mechanism.

But that analysis treats glucagon as a one-target molecule, which it isn't.

The glucagon receptor is not just in the pancreas

Glucagon receptors are expressed in the liver and pancreas — that's the textbook story. But they're also expressed in the brain, brown adipose tissue, and the heart.

In the central nervous system — specifically the hypothalamus — glucagon receptor signaling has appetite-suppressing and energy-expenditure-promoting effects that are distinct from its peripheral glucose-raising effects. Glucagon appears to act as a satiety signal in the brain through mechanisms that parallel, but don't duplicate, GLP-1's central effects.

In brown adipose tissue (BAT), glucagon activates thermogenesis — heat production from fat burning. BAT is metabolically active tissue that can dissipate energy as heat rather than storing it. Glucagon's activation of BAT glucagon receptors increases resting metabolic rate in ways that GLP-1 agonism does not replicate.

This is the key insight: the parts of glucagon signaling that are problematic in T2D (hepatic glucose production, hyperglycemia) are not the same as the parts that are useful in obesity treatment (CNS satiety, BAT thermogenesis, lipolysis). Retatrutide's design tries to capture the latter while neutralizing the former.

How the glucose problem gets solved

The obvious objection: if you're agonizing glucagon receptors, aren't you raising blood sugar?

In isolation, yes. But retatrutide also carries both GLP-1 receptor agonism (which drives insulin release and directly suppresses pancreatic glucagon secretion) and GIP receptor agonism (which further supports insulin secretion and improves insulin sensitivity at adipose tissue). These three signals happen simultaneously in every cell that expresses any of these receptors.

The net effect on blood glucose: essentially neutral or mildly positive. In Phase 2 (the Jastreboff et al. 2023 NEJM paper), retatrutide produced reductions in HbA1c and fasting glucose despite the glucagon agonism component. The GLP-1 and GIP signals appear to dominate the glucose story; the glucagon signal mostly expresses itself through the energy expenditure pathways.

This is consistent with animal models: in rodents and non-human primates, triple agonism that includes glucagon produces greater weight loss and greater metabolic rate increases than dual agonism (GLP-1/GIP alone), without the hyperglycemia you'd expect if glucagon were acting unchecked.

The energy expenditure hypothesis

One of the most clinically important questions in obesity pharmacology is adaptive thermogenesis: as people lose weight, their resting metabolic rate drops, partly as a physiological response to weighing less and partly as a compensatory response to weight loss itself. This metabolic slowdown is a major reason why weight loss plateaus, and why weight regain is so common when treatment stops.

GLP-1 receptor agonists primarily work through appetite suppression (reduced caloric intake). They have modest effects on energy expenditure. Tirzepatide's GIP component adds some improvement in fat metabolism, but tirzepatide's weight loss benefit is still mostly driven by eating less.

Glucagon agonism offers a different lever: it may increase energy expenditure rather than just reducing intake. If retatrutide can activate brown adipose tissue thermogenesis and increase resting metabolic rate — even partially offsetting the adaptive thermogenesis penalty of weight loss — that would explain why its weight loss numbers are higher than what the caloric restriction from GLP-1/GIP agonism alone would predict.

This is a mechanistic hypothesis that's well-supported in animal data and consistent with the Phase 2 human numbers, but it hasn't been directly measured in human Phase 2 subjects. Phase 3 (the TRIUMPH studies) will likely include metabolic rate measurements that test this hypothesis more directly.

The Phase 2 numbers in context

The Jastreboff et al. 2023 Phase 2 trial enrolled 338 participants with obesity (BMI ≥30) across five doses (1 mg, 2 mg, 4 mg, 8 mg, and 12 mg weekly) vs. placebo, over 48 weeks.

The 24.2% figure at 48 weeks compares to tirzepatide's 22.5% at 72 weeks (24 weeks longer) in SURMOUNT-1. Phase 2 and Phase 3 trials aren't directly comparable — Phase 2 is smaller and less rigorous in ways that sometimes inflate results — but the signal is clear enough that retatrutide's weight loss ceiling appears meaningfully higher than the current best approved option.

The curve hadn't plateaued at 48 weeks, either. The trajectory was still declining at the end of the trial, suggesting maximum effect hadn't been reached — which is why the 12 mg dose wasn't necessarily the ceiling.

The trade-offs and unknowns

Triple agonism adds complexity. A few things the field doesn't yet know:

Heart rate. GLP-1 receptor agonists raise resting heart rate by 1–4 bpm on average. Glucagon agonism may add to this (glucagon has positive chronotropic effects on the heart). In Phase 2, heart rate increases with retatrutide were modestly higher than expected from a GLP-1 alone. This is being tracked carefully in Phase 3.

Cardiovascular outcomes. Semaglutide has the SELECT trial (cardiovascular outcomes in people with obesity but without diabetes — positive results). Tirzepatide is running SURMOUNT-MMO. Retatrutide has no cardiovascular outcomes trial data yet. The glucagon component's cardiac effects — positive or negative — remain an open question.

Bone and muscle. Fast weight loss can cause lean mass loss. Retatrutide's extreme weight loss rates may require close attention to protein intake and resistance training to preserve muscle mass. This is common to all high-efficacy GLP-1s but may be more salient with retatrutide given the speed of loss.

GI tolerability. Triple agonism may produce more GI side effects than dual agonism. Phase 2 GI adverse event rates were comparable to tirzepatide, but Phase 3 at the broader population level may tell a different story.

Why the pharmacology matters for patients

Understanding the glucagon mechanism isn't academic — it has practical implications:

1. Retatrutide is not just "more tirzepatide." The mechanism is genuinely different. If someone doesn't respond well to GLP-1 agonists for appetite suppression, the glucagon/energy expenditure component may work through a partially independent pathway.
2. The weight loss is faster. People who've experienced slow progress on tirzepatide or semaglutide often ask whether a different drug would help. Retatrutide's speed of loss may be meaningful for highly motivated patients.
3. The unknowns are real. Novel mechanism = novel risk profile. Retatrutide will need Phase 3 cardiovascular outcomes data before its full risk-benefit picture is clear, which is why the FDA approval timeline matters as much as the efficacy story.

See also:

• How tirzepatide works as a dual agonist
• Retatrutide FDA approval timeline: what's realistic
• GLP-1 side effects overview
• Weight loss: realistic expectations

Related reading

• Tirzepatide complete guide
• SURMOUNT trial results decoded
• What are GLP-1 peptides?